Abstract: A tableted pharmaceutical composition contains nalfurafine or a pharmaceutically acceptable acid addition salt thereof and is excellent in formability and quality control of related substances. The tableted pharmaceutical composition includes nalfurafine or a pharmaceutically acceptable acid addition salt thereof, a binder component, and a carrier, wherein the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof is contained in an amount of 0.1 to 10 ?g, and the weight of the above mentioned binder component is 100,000 to 2,000,000 weight % based on the weight of the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof and 5 to 20 weight % based on the total weight of the resulting pharmaceutical composition, or 20,000 to 500,000 weight % and 1 to 5 weight % based on the total weight of the resulting pharmaceutical composition.

Abstract: A tableted pharmaceutical composition contains nalfurafine or a pharmaceutically acceptable acid addition salt thereof and is excellent in formability and quality control of related substances. The tableted pharmaceutical composition includes nalfurafine or a pharmaceutically acceptable acid addition salt thereof, a binder component, and a carrier, wherein the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof is contained in an amount of 0.1 to 10 ?g, and the weight of the above mentioned binder component is 100,000 to 2,000,000 weight % based on the weight of the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof and 5 to 20 weight % based on the total weight of the resulting pharmaceutical composition, or 20,000 to 500,000 weight % and 1 to 5 weight % based on the total weight of the resulting pharmaceutical composition.

Abstract: A coating agent imparts gas barrier properties to a solid preparation while keeping rapid disintegration properties of the solid preparation, and a coating formed therewith, and provides a coated solid preparation that maintains its rapid disintegration properties and gas barrier properties, and does not generate cracks in the coating under humidified conditions. The coating agent for a solid preparation contains lactose and a swelling clay, but does not contain a water-soluble polymer, wherein the weight of the swelling clay is 20 to 50% with respect to the weight of the solid content.

Abstract: A coating agent imparts gas barrier properties to a solid preparation while keeping rapid disintegration properties of the solid preparation, and a coating formed therewith, and provides a coated solid preparation that maintains its rapid disintegration properties and gas barrier properties, and does not generate cracks in the coating under humidified conditions. The coating agent for a solid preparation contains lactose and a swelling clay, but does not contain a water-soluble polymer, wherein the weight of the swelling clay is 20 to 50% with respect to the weight of the solid content.

Abstract: The present invention relates to a stable tablet comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the tablet according to the present invention comprises: (1) as the effective ingredient, a specific 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt; (2) sodium thiosulfate; (3) at least one selected from the group consisting of saccharides and sugar alcohols; and (4) crospovidone, sodium carboxymethyl starch or a mixture thereof, in which tablet the content of the aforementioned (4) is 1 to 20% by weight per unit weight containing the aforementioned effective ingredient.

Abstract: A montelukast-containing coated solid preparation can be applied to one-dose package, wherein the humidity stability of montelukast or a pharmacologically acceptable salt thereof contained therein is maintained even when the preparation is unpacked. A coated solid preparation contains as an active ingredient montelukast or a pharmacologically acceptable salt thereof and is coated with a coating layer comprising polyvinyl alcohol and swelling clay, wherein the mass ratio of the above-described polyvinyl alcohol to the above-described swelling clay in the above-described coating layer is 8:2 to 3:7.

Abstract: A coated solid preparation includes an active ingredient including valproic acid or a pharmacologically acceptable salt thereof, and a coating layer containing polyvinyl alcohol and swelling clay coating the active ingredient wherein mass ratio of the polyvinyl alcohol to the swelling clay is 8:2 to 3:7 and the swelling clay is dispersed as a laminated structure.

Abstract: It is an object of the present invention to provide a stable solid preparation comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the present invention provides the stable solid preparation comprising the 4,5-epoxymorphinan derivative or the pharmacologically acceptable acid addition salt thereof as the effective ingredient, and comprising sodium thiosulfate, a sugar or a sugar alcohol and hydroxypropylcellulose having a low degree of substitution in an amount of 1 to 30% by weight per weight of a unit containing the effective ingredient.

Abstract: A montelukast-containing coated solid preparation can be applied to one-dose package, wherein the humidity stability of montelukast or a pharmacologically acceptable salt thereof contained therein is maintained even when the preparation is unpacked. A coated solid preparation contains as an active ingredient montelukast or a pharmacologically acceptable salt thereof and is coated with a coating layer comprising polyvinyl alcohol and swelling clay, wherein the mass ratio of the above-described polyvinyl alcohol to the above-described swelling clay in the above-described coating layer is 8:2 to 3:7.

Abstract: The present invention relates to a stable tablet comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the tablet according to the present invention comprises: (1) as the effective ingredient, a specific 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt; (2) sodium thiosulfate; (3) at least one selected from the group consisting of saccharides and sugar alcohols; and (4) crospovidone, sodium carboxymethyl starch or a mixture thereof, in which tablet the content of the aforementioned (4) is 1 to 20% by weight per unit weight containing the aforementioned effective ingredient.

Abstract: A coated solid preparation includes an active ingredient including valproic acid or a pharmacologically acceptable salt thereof, and a coating layer containing polyvinyl alcohol and swelling clay coating the active ingredient wherein mass ratio of the polyvinyl alcohol to the swelling clay is 8:2 to 3:7 and the swelling clay is dispersed as a laminated structure.

Abstract: A reader/writer device performs noncontact communication with a noncontact IC card section (400) to which power is supplied from a power storage section (310) of a portable terminal (300) whereupon the card section is mounted. In the reader/writer device (100), a noncontact communication section (110) transmits and receives information to and from the IC card section (400) by noncontact communication, and a noncontact charging section (120) supplies power to the power storage section (310) in noncontact manner. When noncontact communication with the IC card section (400) cannot be performed by controlling the noncontact communication section (110), a contactless communication/charging control section (130) controls the noncontact charging section (120) to charge the power storage section (310) of the portable terminal (300) in noncontact manner, then, controls the noncontact communication section (110) again to perform noncontact communication.

Abstract: An information-communication terminal device maintaining a low cost of a charger in the case of backup for the device at a charging time, having a high performance security at the backup and allowing users to easily handle the security control after the backup. A charger (107) in the information communication terminal device is charged electric power from a charger (3). An access-release demanding section (105) receives ID data from the charger (3) during the charging time, and demands to release access control to an IC-card-function installed memory card (2). After the IC card-function installed memory card (2) releases the access control, a control section (101) carries out the backup or restore to the IC card-function installed memory card (2).

Abstract: It is an object of the present invention to provide a stable solid preparation comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the present invention provides the stable solid preparation comprising the 4,5-epoxymorphinan derivative or the pharmacologically acceptable acid addition salt thereof as the effective ingredient, and comprising sodium thiosulfate, a sugar or a sugar alcohol and hydroxypropylcellulose having a low degree of substitution in an amount of 1 to 30% by weight per weight of a unit containing the effective ingredient.

Abstract: A reader/writer device performs noncontact communication with a noncontact IC card section (400) to which power is supplied from a power storage section (310) of a portable terminal (300) whereupon the card section is mounted. In the reader/writer device (100), a noncontact communication section (110) transmits and receives information to and from the IC card section (400) by noncontact communication, and a noncontact charging section (120) supplies power to the power storage section (310) in noncontact manner. When noncontact communication with the IC card section (400) cannot be performed by controlling the noncontact communication section (110), a contactless communication/charging control section (130) controls the noncontact charging section (120) to charge the power storage section (310) of the portable terminal (300) in noncontact manner, then, controls the noncontact communication section (110) again to perform noncontact communication.

Abstract: An information-communication terminal device maintaining a low cost of a charger in the case of backup for the device at a charging time, having a high performance security at the backup and allowing users to easily handle the security control after the backup. A charger (107) in the information communication terminal device is charged electric power from a charger (3). An access-release demanding section (105) receives ID data from the charger (3) during the charging time, and demands to release access control to an IC-card-function installed memory card (2). After the IC card-function installed memory card (2) releases the access control, a control section (101) carries out the backup or restore to the IC card-function installed memory card (2).

Abstract: A sustained release preparation of prostaglandin I derivatives, which is highly safe and has stable drug-releasing and absorption properties, is disclosed. In the orally administrable preparation, the active component is a prostaglandin I derivative and the release-controlling component is a hydrogel base.

Abstract: A stable pharmaceutical composition includes a 4,5-epoxy-morphinan derivative, and includes at least one of the group consisting of a water soluble antioxidant, a fat soluble antioxidant, a synergist, a sugar, and a surfactant.

Abstract: The object of the present invention is to provide A transmitter-receiver enables a user to send a mail in an optimal mode even to a portable terminal with lower functional capability without a need for awareness of a plurality of mail service providers. The transmitter-receiver notifies of arrival of the mail at an optimal communication cost depending on the importance of the mail, and unifies a plurality of mail spools. The unified mail spools are controlled by a spool integration unit. The transmitter-receiver according to the present invention comprises a terminal response unit for inquiring capability of a user terminal and a data form converting unit, and the mail is sent in an optimal form to the user terminal. In case the content of the mail cannot be read perfectly, it is designed in such manner that the mail is not deleted from the spool, and arrival of the mail is notified to the user at an optimal communication cost depending on the importance of the mail and position information of the user.

Abstract: A stable pharmaceutical composition includes a 4,5-epoxy-morphinan derivative, and includes at least one of the group consisting of a water soluble antioxidant, a fat soluble antioxidant, a synergist, a sugar, and a surfactant.